Last reviewed · How we verify
COVID-19 Vaccine HIPRA — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
COVID-19 Vaccine HIPRA (COVID-19 Vaccine HIPRA) — Hipra Scientific, S.L.U.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| COVID-19 Vaccine HIPRA TARGET | COVID-19 Vaccine HIPRA | Hipra Scientific, S.L.U | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- COVID-19 Vaccine HIPRA CI watch — RSS
- COVID-19 Vaccine HIPRA CI watch — Atom
- COVID-19 Vaccine HIPRA CI watch — JSON
- COVID-19 Vaccine HIPRA alone — RSS
Cite this brief
Drug Landscape (2026). COVID-19 Vaccine HIPRA — Competitive Intelligence Brief. https://druglandscape.com/ci/covid-19-vaccine-hipra. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab